Detalhe da pesquisa
1.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica;
105(4): 1074-1080, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31248973
2.
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
N Engl J Med;
373(18): 1733-47, 2015 Oct 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26352686
3.
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.
Haematologica;
103(8): 1345-1350, 2018 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29748444
4.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica;
106(1): 291-294, 2021 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32107338
5.
MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.
Hum Mutat;
35(2): 236-47, 2014 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24186861
6.
Autologous Bone Marrow Stem Cells in Patients With Critical Limb Ischaemia not Eligible for Revascularization: A Single Centre Experience.
Angiology;
: 33197231190512, 2023 Sep 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37728082
7.
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.
Adv Hematol;
2022: 5581772, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35126524
8.
Whole-Body Low-Dose Multidetector-Row CT in Multiple Myeloma: Guidance in Performing, Observing, and Interpreting the Imaging Findings.
Life (Basel);
11(12)2021 Nov 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34947851
9.
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Leukemia;
35(1): 235-238, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32286543
10.
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.
Leuk Lymphoma;
56(5): 1510-3, 2015 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25651428